Magnus Medical announces positive long-term data for neuromodulation system

Magnus Medical's study on its neuromodulation system, SAINT, showed positive results in treating treatment-resistant depression with sustained clinical benefits for up to a year. SAINT, which is FDA-cleared, uses MRI-guided repetitive magnetic pulses to target brain areas involved in mood regulation. The therapy involves ten sessions over five days and has previously improved brain activity in patients with major depression.

The study confirmed SAINT's effectiveness as a continuation therapy for patients who previously responded to an acute treatment, demonstrating it as a safe and well-tolerated option that maintains remission for 12 months.

Launched in May, SAINT received a new technology add-on payment (NTAP) from CMS, providing up to $12,675 in additional reimbursement per inpatient treatment. The global neuromodulation market, projected to reach $11.4 billion by 2033, includes major players like Medtronic, Neuronetics, and BrainsWay.